Announcements Trials
Browse Landscape

Phase

Phase 2 35Phase 1 28Phase 1/2 22Phase 3 11Phase NA 6Phase 2/3 3

Status

Completed 5Unknown 4Terminated 3Recruiting 3Active not recruiting 3Not yet recruiting 1

Sponsor Class

NIH 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3

Conditions

Breast Neoplasms 9Carcinoma, Non-Small-Cell Lung 8Prostatic Neoplasms 7Recurrence 6Neoplasm Metastasis 5Colorectal Neoplasms 5Stomach Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Neoplasms 4Lymphoma 4Leukemia, Myeloid, Acute 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Pancreatic Neoplasms 3Ovarian Neoplasms 3Oropharyngeal Neoplasms 3Melanoma 3Lymphoma, Large B-Cell, Diffuse 3Lung Neoplasms 3Glioblastoma 3Gallbladder Neoplasms 3Colonic Neoplasms 3Cholangiocarcinoma 3Thyroid Neoplasms 2Nasopharyngeal Carcinoma 2Myelodysplastic Syndromes 2Mouth Neoplasms 2Leukemia 2Laryngeal Neoplasms 2Hypopharyngeal Neoplasms 2Hyperthermia 2

Interventions

Rituximab 3prednylidene 2deltacortene 2Vincristine 2Specimen Handling 2Prednisone 2Magnetic Resonance Spectroscopy 2Doxorubicin 2Cyclophosphamide 2CT-P10 2venetoclax 1selinexor 1cc-486 1Spinal Puncture 1Hyaluronoglucosaminidase 1Gemcitabine 1Etoposide 1Dexamethasone 1Combined Modality Therapy 1Cisplatin 1Biopsy 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2/3 × Active not recruiting × Lymphoma, Large B-Cell, Diffuse × Clear all
NCT03984448 2026-05-29

Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting
363 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT04799275 2026-05-13

Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting
422 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

NCT04442022 2026-05-06

A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Karyopharm Therapeutics Inc

Phase 2/3 Active not recruiting
501 enrolled
Lymphoid

Recurrence, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡